U.S. Department of Defense sites selected for phase III COVID-19 vaccine trials
On Sept. 3, 2020, the U.S Department of Defense announced that five locations were identified to participate in…
Sanofi and GSK initiated Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
On Sept. 3, 2020, Sanofi and GSK announced the start of the Phase 1/2 clinical trial for their…
Biotechnology | CDC | Infectious Disease | Influenza | NIH | Therapeutics
U.S. Government exercised option to purchase additional RAPIVAB from BioCryst for delivery to Strategic National Stockpile
On Sept. 3, 2020, BioCryst Pharmaceuticals announced that the U.S. Department of Health and Human Services (HHS) had…
BioMedomics’ Sickle SCANﾮ approved by Department of Health in Australia
On Sept. 3, 2020, BioMedomics announced that the Therapeutic Goods Administration, a branch of the Department of Health…
ADMA Biologics launched COVID-19 ImmunoRank Neutralization MICRO-ELISA for detection of SARS-CoV-2
On Sept. 3, 2020, ADMA Biologics announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA…
COVID-19 vaccine study shows severe disease preventable in hamsters
On Sept. 3, 2020, Oregon Health & Science University (OHSU) announced that for the first time, early research…
Biotechnology | COVID-19 | FDA
OraSure’s ORAcollect-RNA device Included in EUA granted to MiraDx for SARS-CoV-2 test
On Sept. 3, 2020, OraSure Technologies announced that its ORAcollect-ﾷRNA (OR-100) collection device was included along with other…
Custom face shields aimed to block droplets, tackled COVID-19 for football players
On Sept. 3, 2020, researchers from the Virginia Tech Helmet Lab announced the development of a football helmet…
Virginia Tech researchers began testing campus wastewater for COVID-19
On Sept. 3, 2020, a team of Virginia Tech researchers announced that they will begin testing wastewater at…
Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 & influenza A/B test for use on cobas 6800/8800 systems
On Sept. 3, 2020, Roche announced that the cobas SARS-CoV-2 & Influenza A/B Test for use on the…
NIH to boost national COVID-19 testing capacity
On Sept. 2, 2020, the NIH announced $129.3 million in scale-up and manufacturing support for a new set…
Mesoblast announced first patients dosed in phase 2/3 trial for COVID-19 ARDS
On Sept. 2, 2020, Mesoblast announced that it had received ethics approval to include Australian hospitals in the…
US Army uniquely poised to battle global pandemic
On Sept. 2, 2020, the U.S. Army Medical Materiel Development Activity reported it was working to develop a…
Broad Institute provided COVID-19 screening for students, faculty and staff at more than 100 colleges and universities
On Sept. 2, 2020, Broad Institute of MIT and Harvard announced it had partnered with 108 public and…
Novavax announced publication of phase 1 data for COVID-19 vaccine candidate in The New England Journal of Medicine
On Sept. 2, 2020, Novavax announced the publication in The New England Journal of Medicine of Phase 1…
Janssen discontinued Pimodivir influenza development program
On Sept. 2, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had made a…
OPKO Health’s BioReference Laboratories announced New York City Schools COVID-19 testing program
On Sept. 2, 2020, BioReference Laboratories, an OPKO Health company, began testing New York City principals, teachers and…
Aegis Sciences awarded $66 million NIH grant to rapidly expand COVID-19 test capacity
On Sept. 2, 2020, Aegis Sciences annunced that it had been selected to participate in the National Institutes…
Biotechnology | COVID-19 | NIH
PathGroup selected by NIH to become RADx program ‘mega-lab’ for COVID-19 testing
On Sept. 2, 2020, PathGroup announced the award of a funding grant from the National Institutes of Health…
Biotechnology | Diagnostics | HIV | Infectious Disease | Non-Profit Research | Organ Transplant | Therapeutics
UT Southwestern performed first HIV-positive-to-HIV-positive organ transplant in Texas
On Sept. 2, 2020, UT Southwestern (UTSW) announced that it had performed the first HIV-positive-to-HIV-positive organ transplant in…
Sonic Healthcare expand COVID-19 testing capacity in US in collaboration with NIH RADx Initiative
On Sept. 2, 2020, Sonic Healthcare USA was awarded a contract from the National Institutes of Health (NIH)…
Ceres received $65M NIH award to expand Nanotrapﾮ particle manufacturing capacity for COVID-19 testing
On Sept. 2, 2020, Ceres Nanosciences announced it had been awarded a contract from the National Institutes of…
NIH awarded MicroGEM $409 million to fast-track rapid, no-lab COVID-19 saliva test
On Sept. 2, 2020, MicroGEM announced it had been awarded up to $40.9 million by the National Institutes…
NIH-supported study to track prevalence and impact of SARS-CoV-2 among pregnant women in low- and middle-income countries
On Sept. 1, 2020, the National Institutes of Health announced that it had launched a study to track…
Titers of antibodies against SARS-CoV2 did not decline within four months
On Sept. 1, 2020, scientists at deCODE genetics in Iceland, a subsidiary of Amgen, published a study in…
MediciNova announced development progress on intranasal formulation of SARS-CoV-2 vaccine for COVID-19
On Sept. 1, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
Arcadia Biosciences acquired proprietary hemp varieties with acquisition of Industrial Seed Innovations
On Sept. 1, 2020, Arcadia Biosciences announced it had completed the purchase of Oregon-based Industrial Seed Innovations (ISI)…
Amyris scaled first fermentation-based cannabinoid
On Sept. 1, 2020, Amyris announced that it had successfully scaled up the commercial production of Cannabigerol (CBG)…
COVID-19 | Disease | FDA | Therapeutics
City of Hope doctors lead novel clinical trial to treat cancer patients with COVID-19
On Sept. 1, 2020, City of Hope announced that it was investigating an innovative treatment for cancer patients…
Sanofi updated Kevzara (sarilumab) phase 3 trial in severe and critically ill COVID-19 patients outside the US
On Sept. 1, 2020, Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara (sarilumab) at…